Douglas W. Mapel, MD, MPH, FCCP
Medical Director, Lovelace Clinic Foundation
Clinical Case Challenge (Online)
The Asthma and Allergy Foundation of America estimates that 20 million people in the United States have asthma. Data from the Centers for Disease Control and Prevention (CDC) indicate that the prevalence of asthma is increasing in the United States and the burden of disease has grown over the last two decades, perhaps more than most health care practitioners realize. This is due largely in part to the variability of the disease; a misclassification may result in inadequate asthma control. Asthmatics also under-perceive and under-communicate the severity of their symptoms and are willing to accept suboptimal control. Choice of an appropriate therapeutic regimen is dependent upon an accurate initial evaluation and frequent follow-up visits assessing symptoms and objective measures of control. This activity has been designed to demonstrate methods to address the challenges associated with the management of asthma and educate the clinician about best assessment and treatment practices.
. Target Audience
This educational activity is designed to meet the needs of pulmonologists, allergy/immunology specialists, primary care providers, nurse practitioners/advance practice nurses, and other healthcare providers with an interest in the treatment of asthma.
Upon completion of this educational activity, the participant should be able to:
Apply updated asthma guidelines when developing asthma treatment plans.
Implement treatment strategies to improve asthma control.
Discuss the appropriate use of maintenance therapies for patients with persistent asthma.
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activities or with the commercial supporter of these continuing education activities. Identified conflict of interest is resolved by AKH prior to accreditation of the activities. AKH planners and reviewers have no relevant financial relationships to disclose.
Douglas W. Mapel, MD, MPH, FCCP, discloses that he has received research support from and served as a consultant to GlaxoSmithKline and Pfizer Pharmaceuticals.
PHYSICIANS: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media, Incorporated. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians.
AKH Inc. designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
NURSES: AKH Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s COA.
AKH Inc. designates this educational activity for 0.5 contact hour (0.05 CEU). Accreditation applies solely to educational activities and does not imply approval or endorsement of any commercial product by the ANCC-COA.
Commercial Support Statements
The opinions expressed in these educational activities are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, AKH Inc., or AstraZeneca. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.